Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $36
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $35 to $36.
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $35 to $36.